| Characteristic . | People With HIV (n = 32) . | Uninfected Controls (n = 37) . |
|---|---|---|
| Age, y, median (IQR) | 57 (55–59) | 58 (56–61) |
| Sex, % male | 88 | 95 |
| Race, % white | 63 | 84 |
| Non-Hispanic, % | 88 | 89 |
| Current smoker, % | 16 | 11 |
| Illicit drug use in the past 2 y, % | 19* | 0* |
| BMI, mean (SD) | 27 (4)* | 30 (5)* |
| Statin use, % | 41 | 41 |
| Antihypertensive use, % | 53 | 43 |
| VACS-1 > 20 points, % | 56* | 24* |
| 3 or more comorbidities, % | 72 | 51 |
| Years since HIV diagnosis, median (IQR) | 21 (16–28) | … |
| Nadir CD4 count, cells/µL, median (IQR) | 200 (85–400) | … |
| CD4 count, cells/µL, median (IQR) | 591 (445–836) | … |
| Detectable HIV-1 RNA at baseline, ≥20 copies/mL, % | 9 | … |
| ART duration, y, median (IQR) | 17 (7–19) | … |
| Receipt of an integrase inhibitor, % | 63 | … |
| Receipt of a protease inhibitor, % | 41 | … |
| Receipt of nonnucleoside reverse transcriptase inhibitor, % | 28 | … |
| Receipt of tenofovir alafenamide or disoproxil fumarate, % | 47 | … |
| Receipt of abacavir, % | 38 | … |
| Hepatitis Ca, % | 13 | 0 |
| IL-6, pg/mL, median (IQR) | 2.08 (1.39–2.55) | 1.79 (1.46–2.58) |
| sTNFR1, pg/mL, median (IQR) | 1180 (945–1491) | 1062 (904–1196) |
| TNF-α, pg/mL, median (IQR) | 1.27 (1.09–1.72)* | 0.99 (0.84–1.28)* |
| hsCRP, mg/L, median (IQR) | 1.88 (0.97–3.77) | 1.07 (0.66–2.42) |
| sCD14, ng/mL, median (IQR) | 1810 (1595–1975)* | 1596 (1309–1691)* |
| sTNFR2, pg/mL, median (IQR)) | 2799 (2134–4111)* | 2289 (1863–2865)* |
| I-FABP, ng/mL, median (IQR) | 331 (201–656) | 209 (89–495) |
| IL-10, pg/mL, median (IQR) | 4.49 (3.29–6.07) | 4.07 (3.04–7.35) |
| Characteristic . | People With HIV (n = 32) . | Uninfected Controls (n = 37) . |
|---|---|---|
| Age, y, median (IQR) | 57 (55–59) | 58 (56–61) |
| Sex, % male | 88 | 95 |
| Race, % white | 63 | 84 |
| Non-Hispanic, % | 88 | 89 |
| Current smoker, % | 16 | 11 |
| Illicit drug use in the past 2 y, % | 19* | 0* |
| BMI, mean (SD) | 27 (4)* | 30 (5)* |
| Statin use, % | 41 | 41 |
| Antihypertensive use, % | 53 | 43 |
| VACS-1 > 20 points, % | 56* | 24* |
| 3 or more comorbidities, % | 72 | 51 |
| Years since HIV diagnosis, median (IQR) | 21 (16–28) | … |
| Nadir CD4 count, cells/µL, median (IQR) | 200 (85–400) | … |
| CD4 count, cells/µL, median (IQR) | 591 (445–836) | … |
| Detectable HIV-1 RNA at baseline, ≥20 copies/mL, % | 9 | … |
| ART duration, y, median (IQR) | 17 (7–19) | … |
| Receipt of an integrase inhibitor, % | 63 | … |
| Receipt of a protease inhibitor, % | 41 | … |
| Receipt of nonnucleoside reverse transcriptase inhibitor, % | 28 | … |
| Receipt of tenofovir alafenamide or disoproxil fumarate, % | 47 | … |
| Receipt of abacavir, % | 38 | … |
| Hepatitis Ca, % | 13 | 0 |
| IL-6, pg/mL, median (IQR) | 2.08 (1.39–2.55) | 1.79 (1.46–2.58) |
| sTNFR1, pg/mL, median (IQR) | 1180 (945–1491) | 1062 (904–1196) |
| TNF-α, pg/mL, median (IQR) | 1.27 (1.09–1.72)* | 0.99 (0.84–1.28)* |
| hsCRP, mg/L, median (IQR) | 1.88 (0.97–3.77) | 1.07 (0.66–2.42) |
| sCD14, ng/mL, median (IQR) | 1810 (1595–1975)* | 1596 (1309–1691)* |
| sTNFR2, pg/mL, median (IQR)) | 2799 (2134–4111)* | 2289 (1863–2865)* |
| I-FABP, ng/mL, median (IQR) | 331 (201–656) | 209 (89–495) |
| IL-10, pg/mL, median (IQR) | 4.49 (3.29–6.07) | 4.07 (3.04–7.35) |
All included participants had baseline inflammatory markers and completed at least 1 acute exercise visit:
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodeficiency virus; hsCRP, highly sensitive C-reactive protein; I-FABP, intestinal fatty acid binding protein; IL, interleukin; IQR, interquartile range; sCD14, soluble CD14; sTNFR, soluble tumor necrosis factor receptor; TNF-α, tumor necrosis factor-α; VACS-1, Veterans Aging Comorbidity Score-1.
*P < .05 for between group difference.
aAll participants with hepatitis C had an undetectable viral load; if hepatitis C was treated, treatment had been completed ≥6 months prior to study initiation.
| Characteristic . | People With HIV (n = 32) . | Uninfected Controls (n = 37) . |
|---|---|---|
| Age, y, median (IQR) | 57 (55–59) | 58 (56–61) |
| Sex, % male | 88 | 95 |
| Race, % white | 63 | 84 |
| Non-Hispanic, % | 88 | 89 |
| Current smoker, % | 16 | 11 |
| Illicit drug use in the past 2 y, % | 19* | 0* |
| BMI, mean (SD) | 27 (4)* | 30 (5)* |
| Statin use, % | 41 | 41 |
| Antihypertensive use, % | 53 | 43 |
| VACS-1 > 20 points, % | 56* | 24* |
| 3 or more comorbidities, % | 72 | 51 |
| Years since HIV diagnosis, median (IQR) | 21 (16–28) | … |
| Nadir CD4 count, cells/µL, median (IQR) | 200 (85–400) | … |
| CD4 count, cells/µL, median (IQR) | 591 (445–836) | … |
| Detectable HIV-1 RNA at baseline, ≥20 copies/mL, % | 9 | … |
| ART duration, y, median (IQR) | 17 (7–19) | … |
| Receipt of an integrase inhibitor, % | 63 | … |
| Receipt of a protease inhibitor, % | 41 | … |
| Receipt of nonnucleoside reverse transcriptase inhibitor, % | 28 | … |
| Receipt of tenofovir alafenamide or disoproxil fumarate, % | 47 | … |
| Receipt of abacavir, % | 38 | … |
| Hepatitis Ca, % | 13 | 0 |
| IL-6, pg/mL, median (IQR) | 2.08 (1.39–2.55) | 1.79 (1.46–2.58) |
| sTNFR1, pg/mL, median (IQR) | 1180 (945–1491) | 1062 (904–1196) |
| TNF-α, pg/mL, median (IQR) | 1.27 (1.09–1.72)* | 0.99 (0.84–1.28)* |
| hsCRP, mg/L, median (IQR) | 1.88 (0.97–3.77) | 1.07 (0.66–2.42) |
| sCD14, ng/mL, median (IQR) | 1810 (1595–1975)* | 1596 (1309–1691)* |
| sTNFR2, pg/mL, median (IQR)) | 2799 (2134–4111)* | 2289 (1863–2865)* |
| I-FABP, ng/mL, median (IQR) | 331 (201–656) | 209 (89–495) |
| IL-10, pg/mL, median (IQR) | 4.49 (3.29–6.07) | 4.07 (3.04–7.35) |
| Characteristic . | People With HIV (n = 32) . | Uninfected Controls (n = 37) . |
|---|---|---|
| Age, y, median (IQR) | 57 (55–59) | 58 (56–61) |
| Sex, % male | 88 | 95 |
| Race, % white | 63 | 84 |
| Non-Hispanic, % | 88 | 89 |
| Current smoker, % | 16 | 11 |
| Illicit drug use in the past 2 y, % | 19* | 0* |
| BMI, mean (SD) | 27 (4)* | 30 (5)* |
| Statin use, % | 41 | 41 |
| Antihypertensive use, % | 53 | 43 |
| VACS-1 > 20 points, % | 56* | 24* |
| 3 or more comorbidities, % | 72 | 51 |
| Years since HIV diagnosis, median (IQR) | 21 (16–28) | … |
| Nadir CD4 count, cells/µL, median (IQR) | 200 (85–400) | … |
| CD4 count, cells/µL, median (IQR) | 591 (445–836) | … |
| Detectable HIV-1 RNA at baseline, ≥20 copies/mL, % | 9 | … |
| ART duration, y, median (IQR) | 17 (7–19) | … |
| Receipt of an integrase inhibitor, % | 63 | … |
| Receipt of a protease inhibitor, % | 41 | … |
| Receipt of nonnucleoside reverse transcriptase inhibitor, % | 28 | … |
| Receipt of tenofovir alafenamide or disoproxil fumarate, % | 47 | … |
| Receipt of abacavir, % | 38 | … |
| Hepatitis Ca, % | 13 | 0 |
| IL-6, pg/mL, median (IQR) | 2.08 (1.39–2.55) | 1.79 (1.46–2.58) |
| sTNFR1, pg/mL, median (IQR) | 1180 (945–1491) | 1062 (904–1196) |
| TNF-α, pg/mL, median (IQR) | 1.27 (1.09–1.72)* | 0.99 (0.84–1.28)* |
| hsCRP, mg/L, median (IQR) | 1.88 (0.97–3.77) | 1.07 (0.66–2.42) |
| sCD14, ng/mL, median (IQR) | 1810 (1595–1975)* | 1596 (1309–1691)* |
| sTNFR2, pg/mL, median (IQR)) | 2799 (2134–4111)* | 2289 (1863–2865)* |
| I-FABP, ng/mL, median (IQR) | 331 (201–656) | 209 (89–495) |
| IL-10, pg/mL, median (IQR) | 4.49 (3.29–6.07) | 4.07 (3.04–7.35) |
All included participants had baseline inflammatory markers and completed at least 1 acute exercise visit:
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodeficiency virus; hsCRP, highly sensitive C-reactive protein; I-FABP, intestinal fatty acid binding protein; IL, interleukin; IQR, interquartile range; sCD14, soluble CD14; sTNFR, soluble tumor necrosis factor receptor; TNF-α, tumor necrosis factor-α; VACS-1, Veterans Aging Comorbidity Score-1.
*P < .05 for between group difference.
aAll participants with hepatitis C had an undetectable viral load; if hepatitis C was treated, treatment had been completed ≥6 months prior to study initiation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
